Apontis Pharma AG
Develops and markets fixed-dose combination drugs (Single Pills) for chronic diseases.
APPH | F
Overview
Corporate Details
- ISIN(s):
- DE000A3CMGM5 (+1 more)
- LEI:
- 894500ETO1J6MR8PDF91
- Country:
- Germany
- Address:
- Alfred-Nobel-Straße 10, 40789 Monheim am Rhein
- Website:
- https://apontis-pharma.de/en/
- Sector:
- Manufacturing
Description
Apontis Pharma AG is a pharmaceutical company that specializes in the development, marketing, and distribution of 'Single Pills'. These are fixed-dose combination drugs that unite two or three active pharmaceutical ingredients into a single tablet. The company's portfolio primarily focuses on treating cardiovascular diseases and other chronic conditions. By simplifying treatment regimens, the Single Pill approach aims to improve patient adherence and therapy outcomes, offering medical and economic benefits to the healthcare system. Apontis Pharma also engages in co-marketing activities for established pharmaceutical products.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2023-05-09 07:30 |
APONTIS PHARMA in Q1 2023 records decline in sales and earnings as expected 20…
|
English | 46.6 KB | ||
| 2023-05-08 07:30 |
APONTIS PHARMA: Keeping up high pace in expansion of Single Pill portfolio - Ne…
|
English | 11.4 KB | ||
| 2023-05-05 15:35 |
APONTIS PHARMA AG: Silke Reineke, buy
|
English | 8.2 KB | ||
| 2023-05-02 21:50 |
APONTIS PHARMA AG adjusts forecast for fiscal year 2023
|
English | 7.3 KB | ||
| 2023-04-27 07:30 |
APONTIS PHARMA with first in-licensing of a Single Pill with two active ingredi…
|
English | 9.7 KB | ||
| 2023-04-12 07:30 |
APONTIS PHARMA: New development partnership with Midas Pharma Expansion of Sin…
|
English | 12.2 KB | ||
| 2023-03-30 00:00 |
Annual financial statements 2022
|
German | 8.8 MB | ||
| 2023-03-09 07:30 |
APONTIS PHARMA with successful financial year 2022: Revenue and EBITDA forecast…
|
English | 21.6 KB | ||
| 2023-02-14 07:30 |
APONTIS PHARMA accelerates expansion of Single Pill portfolio with second of th…
|
English | 9.6 KB | ||
| 2023-01-31 07:30 |
APONTIS PHARMA extends portfolio for the treatment of hypertension and hyperlip…
|
English | 9.6 KB | ||
| 2022-12-14 00:00 |
Jahresabschluss zum Geschäftsjahr vom 01.01.2021 bis zum 31.12.2021
|
German | 22.7 KB | ||
| 2022-11-29 07:30 |
APONTIS PHARMA: Number of announced market launches increases to ten Single Pil…
|
English | 10.2 KB | ||
| 2022-11-10 07:30 |
APONTIS PHARMA confirms 2022 forecast after successful nine-month period Stron…
|
English | 41.4 KB | ||
| 2022-11-10 00:00 |
9M Präsentation (EN)
|
German | 3.3 MB | ||
| 2022-11-10 00:00 |
9M Results Presentation
|
English | 3.3 MB |
Automate Your Workflow. Get a real-time feed of all Apontis Pharma AG filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Apontis Pharma AG
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Apontis Pharma AG via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-05-14 | Milz, Thomas | Board | Buy | None | 8,960.00 EUR |
| 2024-05-14 | be executive GmbH | Close relation | Buy | None | 8,880.00 EUR |
| 2024-05-13 | Zimmermann, Thomas | Other | Buy | None | 10,128.00 EUR |
| 2024-05-13 | Zimmermann, Thomas | Other | Buy | None | 3,396.00 EUR |
| 2024-05-13 | Zimmermann, Thomas | Other | Buy | None | 1,692.00 EUR |
| 2024-05-13 | Zimmermann, Thomas | Other | Buy | None | 1,688.00 EUR |
| 2023-05-05 | Reineke, Silke | Close relation | Buy | None | 36,625.00 EUR |
| 2023-05-05 | Milz, Thomas | Board | Buy | None | 14,360.00 EUR |
Peer Companies
